Caribou Biosciences, Inc.

As of July 31, 2025, Caribou Biosciences, Inc. shows a mildly bullish technical trend, but mixed indicators and underperformance compared to the S&P 500 suggest caution.

As of June 17, 2025, Caribou Biosciences, Inc. is in a neutral technical stance with mixed signals, indicating a consolidation phase rather than a clear bullish or bearish trend.

Caribou Biosciences, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $2 million and a net loss of $40 million. It has a market cap of $107.89 million and key metrics indicating significant financial challenges, including a negative return on equity and no dividend yield.

As of Jun 18, Caribou Biosciences, Inc. has a market capitalization of 107.89 million and reported net sales of 9.91 million with a net profit of -147.86 million over the latest four quarters.